VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH AL 2020 | MBG453 with hypomethylating agents in AML and high-risk MDS

Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia, details de results of the Phase 1b multicenter, open-label study of the anti-TIM-3 antibody MBG453 in combination with hypomethylating agents in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter